Physician profile
Grace C Brummer
NPI 1902394463
$4,114.66
in general payments reported to CMS, 2019-2025
22 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.54 · 2021: $69.00 · 2022: $402 · 2023: $1,171 · 2024: $865 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,443 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,442.63 |
| Education | $175.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.31 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $610.31 | 2022-2025 | |
| Janssen Biotech, INC. | $431.26 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $284.32 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $276.53 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $235.99 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $218.12 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $214.62 | 2023-2025 | |
| Ucb, INC. | $193.87 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $143.17 | 2024-2025 | |
| Lilly USA, LLC | $140.21 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $137.02 | 2022-2025 | Sotyktu |
| Amgen INC. | $75.79 | 2022-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $69.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $59.42 | 2022-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $32.42 | 2023-2024 | Opzelura |
| Organon LLC | $26.55 | 2025 | |
| Nobelpharma America, LLC | $24.34 | 2025 | |
| Journey Medical Corporation | $21.92 | 2025 | |
| Paratek Pharmaceuticals, INC. | $21.48 | 2024 | Nuzyra |
| Biowound Solutions, INC. | $15.41 | 2025 | Bio-Connekt |
| Botanix Sb INC | $14.60 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Brummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.